| Date | Time | Source | Headline | Symbol | Company |
| 06/14/2010 | 2:11PM | PR Newswire (US) | Aeterna Zentaris to Present Poster on Pharmacological and Toxicological Data on Oral Synthetic Growth Hormone Secretagogue/Ghrel | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 06/08/2010 | 9:05AM | PR Newswire (US) | Aeterna Zentaris Reports Final Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine in the Trea | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 06/08/2010 | 9:00AM | PR Newswire (US) | Keryx Reports Final Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Trea | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 06/07/2010 | 8:35AM | PR Newswire (US) | Aeterna Zentaris Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors, Includi | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 06/07/2010 | 7:30AM | PR Newswire (US) | Aeterna Zentaris Presents Positive Efficacy and Safety Data for AEZS-108 in Ovarian Cancer at ASCO Meeting | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 06/02/2010 | 7:30AM | PR Newswire (US) | Aeterna Zentaris to Present at Upcoming Needham Annual Healthcare Conference on June 10, 2010 | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/21/2010 | 8:35AM | PR Newswire (US) | Aeterna Zentaris: Data on Lead Anticancer Compounds Perifosine and AEZS-108 to be Presented at Upcoming ASCO Annual Meeting | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/18/2010 | 1:16PM | Edgar (US Regulatory) | Statement of Beneficial Ownership (SC 13D) | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/17/2010 | 10:54AM | Edgar (US Regulatory) | Report of Foreign Issuer (6-K) | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/17/2010 | 8:35AM | PR Newswire (US) | Æterna Zentaris: Publication in the Journal of the National Cancer Institute Demonstrates Perifosine Single Agent Potential in N | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/17/2010 | 7:30AM | PR Newswire (US) | Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Ca | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/14/2010 | 2:30PM | Edgar (US Regulatory) | Statement of Beneficial Ownership (SC 13D) | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/13/2010 | 4:49PM | Edgar (US Regulatory) | Report of Foreign Issuer (6-K) | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/13/2010 | 2:24PM | Edgar (US Regulatory) | Report of Foreign Issuer (6-K) | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/13/2010 | 6:45AM | PR Newswire (US) | Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/12/2010 | 7:30AM | PR Newswire (US) | Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/11/2010 | 7:30AM | PR Newswire (US) | Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference on May 18, 2010 | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/07/2010 | 10:13AM | Edgar (US Regulatory) | Amended Report of Foreign Issuer (6-K/A) | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/07/2010 | 5:50AM | GlobeNewswire Inc. | Stock Alert for AEterna Zentaris Inc. Issued by MicroStockProfit | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/06/2010 | 8:00AM | PR Newswire (US) | Aeterna Zentaris to Announce First Quarter 2010 Financial and Operating Results and Hold Annual Shareholder Meeting on May 13, 2 | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 05/06/2010 | 7:30AM | PR Newswire (US) | Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 04/27/2010 | 10:45AM | PR Newswire (US) | Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 04/26/2010 | 5:29PM | Edgar (US Regulatory) | Statement of Ownership (SC 13G) | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 04/20/2010 | 4:37PM | Edgar (US Regulatory) | Report of Foreign Issuer (6-K) | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 04/20/2010 | 2:00PM | PR Newswire (US) | Aeterna Zentaris Presents a Poster on its Dual Inhibitors for PI3K and Erk, as well as an Oral Presentation Reporting Data on Se | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 04/20/2010 | 8:35AM | PR Newswire (US) | Aeterna Zentaris: Poster Highlighting Preclinical Activity of Single-Agent Perifosine to be Presented at 2010 AACR Annual Meetin | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 04/20/2010 | 8:00AM | PR Newswire (US) | Aeterna Zentaris Receives US$15 Million on Closing of Registered Direct Offering | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 04/20/2010 | 5:50AM | GlobeNewswire Inc. | Biopharma Stock Alert for AEterna Zentaris Inc. Issued by MicroStockProfit | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 04/16/2010 | 1:23PM | Edgar (US Regulatory) | Report of Foreign Issuer (6-K) | NASDAQ:AEZS | Aeterna Zentaris Inc |
| 04/16/2010 | 12:07PM | Edgar (US Regulatory) | Prospectus filed pursuant to Rule 424(b)(5) (424B5) | NASDAQ:AEZS | Aeterna Zentaris Inc |